Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sucralfate--safety and side effects.

I N Marks1

  • 1Dept. of Medicine, University of Cape Town, South Africa.

Scandinavian Journal of Gastroenterology. Supplement
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The treatment of peptic ulcer disease.

Current opinion in gastroenterology·2006
Same author

The medical treatment of peptic ulcer disease.

Current opinion in gastroenterology·2006
Same author

The treatment of peptic ulcer disease.

Current opinion in gastroenterology·2006
Same author

The pepsinogen releasing effect of Helicobacter pylori lipopolysaccharide.

Helicobacter·2002
Same author

Helicobacter pylori in Africa: observations on an 'enigma within an enigma'.

Journal of gastroenterology and hepatology·1999
Same author

Helicobacter pylori: therapeutic targets.

The Yale journal of biology and medicine·1999
Same journal

Abstract from the 41st Nordic Gastroenterology Congress, 8-11 June 2010, Copenhagen, Denmark.

Scandinavian journal of gastroenterology. Supplement·2010
Same journal

Abstracts from the XL Nordic Meeting of Gastroenterology, June 8-11, 2009, Stavanger, Norway.

Scandinavian journal of gastroenterology. Supplement·2009
Same journal

Abstracts of the 39th Nordic Meeting of Gastroenterology, 30th Nordic Meeting of Digestive Endoscopy, 18th Nordic Meeting of Gastrointestinal Motility, and the Annual Endoscopy/Gastroenterology Nurses'/Assistants' Meeting Post-graduate course, 4-6 June 2008, Helsinki, Finland.

Scandinavian journal of gastroenterology. Supplement·2008
Same journal

Abstracts from the XXXVIII Nordic Meeting of Gastroenterology, XXIX Nordic Meeting of Digestive Endoscopy, XVII Nordic Meeting of Gastrointestinal Motility, 6-9 June 2007, Reykjavik, Iceland.

Scandinavian journal of gastroenterology. Supplement·2007
Same journal

Abstracts of the XXXVII Nordic Meeting of Gastroenterology, 3-5 May 2006, Vasteras, Sweden.

Scandinavian journal of gastroenterology. Supplement·2006
Same journal

Novel approaches in the outpatient care of patients with chronic inflammatory bowel disease.

Scandinavian journal of gastroenterology. Supplement·2006
See all related articles

Sucralfate is generally safe, but caution is advised for patients with kidney failure due to potential aluminum toxicity. Drug interactions with sucralfate are possible but manageable with proper timing.

Area of Science:

  • Pharmacology
  • Nephrology
  • Toxicology

Background:

  • Sucralfate is a medication used for gastrointestinal issues.
  • Concerns exist regarding aluminum absorption and toxicity from sucralfate, particularly in patients with impaired kidney function.

Purpose of the Study:

  • To evaluate the safety profile of sucralfate concerning aluminum absorption, excretion, accumulation, and toxicity.
  • To assess the impact of sucralfate on phosphate levels and its potential drug-drug interactions.

Main Methods:

  • Review of existing literature on sucralfate's pharmacokinetic and toxicological properties.
  • Analysis of clinical data regarding aluminum levels, phosphate metabolism, and drug interactions.

Main Results:

Related Experiment Videos

  • Sucralfate leads to minimal aluminum absorption in healthy individuals, with efficient renal excretion.
  • Patients with advanced renal failure are at risk of aluminum toxicity.
  • Sucralfate effectively reduces hyperphosphatemia in chronic uremia but can raise blood aluminum levels.
  • Sucralfate can impair the bioavailability of certain drugs, including phenytoin and fluoroquinolones, necessitating dose separation.

Conclusions:

  • Sucralfate is safe for patients with normal renal function.
  • Caution and monitoring are essential for patients with renal impairment due to potential aluminum accumulation and toxicity.
  • Drug interactions with sucralfate can be managed by administering interacting drugs at least 2 hours prior to sucralfate.